Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 479 results found since Jan 2013.

Evaluation of Safety and Side Effects COVID-19 Vaccine in Cancer Patients Being Treated
Asian Pac J Cancer Prev. 2022 Apr 1;23(4):1263-1270. doi: 10.31557/APJCP.2022.23.4.1263.ABSTRACTAccording to the instructions of Iran's National Corona Response Committee in the Iranian Ministry of Health and Medical Education, patients undergoing treatments for their cancer are prioritized in Covid-19 vaccination. The present study was therefore conducted to investigate the toxicity and acute side-effects of a Covid-19 vaccine in cancer patients presenting to Medical Oncology Clinic of Kermanshah University of Medical Science. After excluding the patients with active infection and the recently-infected ones with Covid-19,...
Source: Asian Pacific Journal of Cancer Prevention - April 29, 2022 Category: Cancer & Oncology Authors: Mozaffar Aznab Maryam Chalehchaleh Somayeh Dokoshkani Maryam Rezaei Source Type: research

The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers
CONCLUSION: We conclude that tumor cells can be harvested from patients with metastatic or stage II-III breast cancer to prepare autologous GM-CSF-secreting vaccines that induce coordinated immune responses with limited toxicity. TRIAL REGISTRATION AND DATE OF REGISTRATION: clinicaltrials.gov, NCT00317603 (April 25, 2006) and NCT00880464 (April 13, 2009).PMID:35482127 | PMC:PMC9046531 | DOI:10.1007/s10549-022-06562-y
Source: Cell Research - April 28, 2022 Category: Cytology Authors: Karen S Anderson Timothy K Erick Meixuan Chen Heather Daley Margaret Campbell Yolonda Colson Martin Mihm Labib R Zakka Marika Hopper William Barry Eric P Winer Glenn Dranoff Beth Overmoyer Source Type: research

IJERPH, Vol. 19, Pages 5191: Effect of Different Educational Interventions on Knowledge of HPV Vaccination and Cervical Cancer among Young Women: A Preliminary Report
zunori Nagasaka The incidence and mortality rates of cervical cancer are rising among young women in Japan. In November 2021, the Japanese Ministry of Health, Labour, and Welfare reinstated the active recommendation for the human papillomavirus (HPV) vaccine, which was discontinued in June 2013 due to reports of adverse reactions, including chronic pain and motor dysfunction, following vaccination. However, vaccine hesitancy among the younger generation remains, and it is essential to identify the barriers in vaccination uptake. Therefore, we aimed to conduct a randomized study using different methods of providing educ...
Source: International Journal of Environmental Research and Public Health - April 25, 2022 Category: Environmental Health Authors: Yuko Takahashi Haruka Nishida Takayuki Ichinose Yuko Miyagawa Koichiro Kido Haruko Hiraike Hirono Ishikawa Kazunori Nagasaka Tags: Article Source Type: research

The Connection Between IBD and Aging
Inflammatory bowel disease (IBD) has long been thought of as an ailment of middle, or even young, adulthood. The chronic illness—which includes Crohn’s disease and ulcerative colitis, and can cause abdominal pain, diarrhea, bleeding, and decreased quality of life—impacts about 3.1 million people in the U.S. However, it is far from a disease only of the young and middle-aged. More than a quarter of people with IBD are elderly, a figure that is projected to climb to 30% by 2030, according to a 2021 Gastroenterology & Hepatology article. Even more underappreciated is the growing population of people who ...
Source: TIME: Health - April 8, 2022 Category: Consumer Health News Authors: Katherine Harmon Courage Tags: Uncategorized Disease healthscienceclimate Source Type: news

Janssen Announces Health Canada Approval of RYBREVANT ® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Toronto, ON, April 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) approving RYBREVANT® (amivantamab), a fully-human, bispecific antibody, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.[i] Health Canada NOC/c is granted to promising new therapies for patients diagnosed with serious, life-threate...
Source: Johnson and Johnson - April 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Who ’ s Afraid of Needles?
Discussion There are products that are valued highly because of their design and function are elegantly suited for their use. Books would be one example and the hypodermic needle is another. Medical hypodermic needles are used for accessing bodily spaces (e.g. vascular, peritoneal, subarachnoid, dermal, etc.), obtaining specimens (both solid tissue and liquid) and to deliver drugs, biologicals, fluids and other treatments to patients. Medical procedures involving some type of needle are the most common procedures taught to health care providers. A brief history of syringes and hypodermic needles can be found here. A variet...
Source: PediatricEducation.org - April 4, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Weekly Overseas Health IT Links – 26th March, 2022.
Here are a few I came across last week.Note: Each link is followed by a title and few paragraphs. For the full article click on the link above title of the article. Note also that full access to some links may require site registration or subscription payment.-----https://mhealthintelligence.com/news/55-of-telehealth-providers-frustrated-with-overblown-patient-expectations55% of Telehealth Providers Frustrated With Overblown Patient ExpectationsProviders also cited their ability to provide quality care and technical difficulties as among their top frustrations with telehealth, a new survey shows.ByAnuja VaidyaMarch 18, 202...
Source: Australian Health Information Technology - March 26, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news

The (sort of, partial) Father mRNA Vaccines Who Now Spreads Vaccine Misinformation (Part 1)
By DAVID WARMFLASH, MD Robert W. Malone, MD MS, is a physician-scientist who will live in infamy, thanks to the Joe Rogan Experience Podcast boosting his visibility this past December regarding his criticism of COVID-19 vaccines, particularly the mRNA vaccines (Moderna and Pfizer-BioNTech). Subsequently, Malone was banned from Twitter, which further boosted his celebrity status. Describing himself as the inventor of mRNA vaccine technology, he has been reaching a growing number of people with a narrative that makes COVID-19 vaccination sound scary. We cannot embed clips from the Rogan interview, which lasted about three...
Source: The Health Care Blog - March 17, 2022 Category: Consumer Health News Authors: matthew holt Tags: COVID-19 Health Policy antivaxxer COVID-19 vaccine David Warmflash Joe Rogan Robert Malone Source Type: blogs

NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2022 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NIDCR News Science Advances   NIDCR News NIH & NIDCR Release “Oral Health in America: Advances and Challenges” In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For more ...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news

U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
DiscussionThe inactivated SARS-CoV-2 vaccine (BBIBP-CorV) is a tolerable and effective method to prevent COVID-19.
Source: Frontiers in Endocrinology - March 1, 2022 Category: Endocrinology Source Type: research

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
CONCLUSION: In participants with past or active neoplasms, BNT162b2 vaccine has a similar efficacy and safety profile as in the overall trial population. These results can inform BNT162b2 use during the COVID-19 pandemic and future trials in participants with cancer. Clinical trial number: NCT04368728.PMID:35131133 | PMC:PMC8702495 | DOI:10.1016/j.vaccine.2021.12.046
Source: Vaccine - February 8, 2022 Category: Allergy & Immunology Authors: Stephen J Thomas John L Perez Stephen P Lockhart Subramanian Hariharan Nicholas Kitchin Ruth Bailey Katherine Liau Eleni Lagkadinou Özlem Türeci Ugur Şahin Xia Xu Kenneth Koury Samuel S Dychter Claire Lu Teresa C Gentile William C Gruber Source Type: research